Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Kazia Therapeutics Ltd / Equity Bottom-Up

<p>Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential regulatory filing, if data are positive. Recent C-suite appointments in the United States suggest an increased focus on commercialization, particularly in the US market. Second asset EVT801 has progressed to human studies, with the first patient enrolled in a Phase I trial in France in November 2021 and interim data expected in H2 CY22. We expect CY22 to be catalyst rich, with data anticipated from multiple investigator-sponsored studies evaluating paxalisib in the treatment of brain metastases (BMs), as well as pediatric brain cancers such as diffuse intrinsic pontine glioma (DIPG). Positive readouts from any study alone could potentially trigger a re-rating for the stock. We have increased our valuation to US$294m or US$22.28 per basic ADR mainly due to rolling forward our NPV, partially offset by lower cash and higher R&D estimates.</p>

Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential regulatory filing, if data are positive. Recent C-suite appointments in the United States suggest an increased focus on commercialization, particularly in the US market. Second asset EVT801 has progressed to human studies, with the first patient enrolled in a Phase I trial in France in November 2021 and interim data expected in H2 CY22. We expect CY22 to be catalyst rich, with data anticipated from multiple investigator-sponsored studies evaluating paxalisib in the treatment of brain metastases (BMs), as well as pediatric brain cancers such as diffuse intrinsic pontine glioma (DIPG). Positive readouts from any study alone could potentially trigger a re-rating for the stock. We have increased our valuation to US$294m or US$22.28 per basic ADR mainly due to rolling forward our NPV, partially offset by lower cash and higher R&D estimates.

Kazia Therapeutics - Several upcoming catalysts

Australia

Kazia Therapeutics Limited operates as an biotechnology company. The Company develops anti-cancer drugs, as well as provides pharmaceutical research and development technology solutions. Kazia Therapeutics serves customers globally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kazia Therapeutics Ltd (KZIA US)

Kazia Therapeutics - Several upcoming catalysts

Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)